BlackRock Inc. Takes Position in Insulet Corporation $PODD

Key Points

• BlackRock acquired 6.69 million Insulet shares worth approximately $1.02 billion, giving it a 9.66% stake in the medical-device company. Several other institutional investors also initiated positions during the second quarter.
• Analysts have recently lowered their price targets and ratings, with MarketBeat reporting a consensus rating of “Hold” and an average price target of $195.40.
• Insulet exceeded quarterly expectations with adjusted EPS of $1.66 and revenue of $801.7 million, up 23.5% year over year, but the company faces shareholder litigation allegations tied to manufacturing quality, product safety and Omnipod device corrections.

BlackRock Inc. bought a new position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,690,192 shares of the medical instruments supplier's stock, valued at approximately $1,018,582,000. BlackRock Inc. owned 9.66% of Insulet at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC purchased a new position in Insulet in the second quarter valued at approximately $676,000. Deutsche Bank AG purchased a new stake in shares of Insulet in the second quarter worth about $51,153,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Insulet in the second quarter valued at about $26,412,000. OneDigital Investment Advisors LLC acquired a new stake in shares of Insulet in the second quarter valued at about $6,741,000. Finally, Plato Investment Management Ltd acquired a new position in Insulet during the 2nd quarter worth approximately $357,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PODD. Sanford C. Bernstein lowered their price objective on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Wells Fargo & Company downgraded shares of Insulet from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. Barclays cut their price objective on shares of Insulet from $286.00 to $198.00 and set an "underweight" rating on the stock in a report on Thursday, May 7th. Stifel Nicolaus decreased their price objective on shares of Insulet from $225.00 to $180.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings lowered Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, June 24th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $195.40.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm's stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company's stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Insulet Price Performance

NASDAQ PODD opened at $148.16 on Friday. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88. The firm has a market capitalization of $10.27 billion, a PE ratio of 27.69, a P/E/G ratio of 1.16 and a beta of 1.10. The company's 50 day simple moving average is $154.67 and its 200 day simple moving average is $184.81. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. Insulet's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source